Up next

Autoplay

Link between blood involvement and HRQoL in CTCL patients receiving mogamulizumab

3 Views • 08/09/23
Share
Embed
administrator
administrator
Subscribers
0

Pablo Ortiz Romero, MD, PhD, University Complutense, Hospital 12 de Octubre, Medical School, Institute i+12, Madrid, Spain, comments on the association between health-related quality of life (HRQoL) outcomes and blood involvement for patients with cutaneous T-cell lymphoma (CTCL) receiving mogamulizumab. This interview took place at the EORTC Cutaneous Lymphoma Group 20-21 meeting in Marseille.

Show more
0 Comments sort Sort By
Facebook Comments

Up next

Autoplay